Vicor Technologies, Inc. Names Dr. Edward Lundy Chairman of Its Scientific Advisory Board

December 15, 2010 |

6 min read

BOCA RATON, FL--(Marketwire - December 15, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Edward F. Lundy, MD, PhD, was named Chairman of the Company’s Scientific Advisory Board, effective December 1. Vicor Technologies, Inc. (OTCBB: VCRT) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dr. Lundy is a recognized cardiothoracic surgeon whose work with trauma cases and research into the effects and causes of cardiac arrest make him an especially perfect match for Vicor. We are extremely gratified to have him serving as the Chairman of our Scientific Advisory Board,” stated Mr. Fater.

As Chairman of the Scientific Advisory Board, Dr. Lundy will interact with Vicor’s researchers and marketers to help identify new markets for the Company’s products and serve, in conjunction with Dr. Daniel Weiss, Vicor’s Chief Medical Officer, as a spokesperson on medical affairs related to Vicor’s target markets. Dr. Lundy has been a member of Vicor’s Scientific Advisory Board since 2007. Vicor’s Scientific Advisory Board is composed of accomplished professionals in the medical, academic, and life sciences arenas.

Dr. Edward Lundy is Chief of Cardiac Surgery and Director of the Active International Cardiovascular Institute at Good Samaritan Hospital in Suffern, NY. Under Dr. Lundy’s stewardship, Active International has received numerous honors, including recognition as one of the Society of Thoracic Surgeons Top 5% of Open Heart Programs, and a recipient of the Health Grades Open Heart Surgery Center of Excellence Award.

Earlier, Dr. Lundy was a staff cardiothoracic surgeon and director of the Open Heart Surgery Program at Lancaster General Hospital and Lancaster Regional Medical Center in Pennsylvania. During Dr. Lundy’s tenure, Lancaster General Hospital’s Open Heart Program received numerous honors and was among U.S. News & World Report’s Top 50 Open Heart Programs (1999-2000).

Dr. Lundy’s research into the effects and causes of cardiac arrest has been published in respected medical journals, including, the Journal of Thoracic Cardiovascular Surgery, Stroke, the Journal of Critical Care, the Annals of Thoracic Surgery, Surgery, and Vascular Surgery. Groups before which Dr. Lundy has presented abstracts include the Central Surgical Society, the American College of Surgeons, the Federation of American Societies for Experimental Biology, and the Association of Veterans Administration Surgeons.

Dr. Lundy is a member of the Fellow American College Surgeons (FACS), the Society of Thoracic Surgeons (STS), and the Fellow American College of Cardiology (FACC). He holds a PhD in Physiology from the University of Michigan-Rackham School of Graduate Studies. He earned a MD with Distinction at the University of Michigan Medical School and a BS with honors in Biology from Villanova University.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i®values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) to be used in patients undergoing cardiovascular disease testing and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-26